IN2015DN03928A - - Google Patents

Download PDF

Info

Publication number
IN2015DN03928A
IN2015DN03928A IN3928DEN2015A IN2015DN03928A IN 2015DN03928 A IN2015DN03928 A IN 2015DN03928A IN 3928DEN2015 A IN3928DEN2015 A IN 3928DEN2015A IN 2015DN03928 A IN2015DN03928 A IN 2015DN03928A
Authority
IN
India
Prior art keywords
compound
formula
mek
inhibitor
disclosed
Prior art date
Application number
Other languages
English (en)
Inventor
Sriram Naganathan
Nathan Guz
Matthew Pfeiffer
C Gregory Sowell
Tracy Bostick
Jason Yang
Amit Srivastava
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of IN2015DN03928A publication Critical patent/IN2015DN03928A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IN3928DEN2015 2012-10-12 2013-10-14 IN2015DN03928A (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261713104P 2012-10-12 2012-10-12
PCT/US2013/064866 WO2014059422A1 (en) 2012-10-12 2013-10-14 Novel process for making compounds for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
IN2015DN03928A true IN2015DN03928A (cs) 2015-10-02

Family

ID=49474740

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3928DEN2015 IN2015DN03928A (cs) 2012-10-12 2013-10-14

Country Status (31)

Country Link
US (4) US9771347B2 (cs)
EP (1) EP2909188B1 (cs)
JP (2) JP6300042B2 (cs)
KR (1) KR102204520B1 (cs)
CN (2) CN104837826B (cs)
AU (1) AU2013328929B2 (cs)
BR (1) BR112015008113B1 (cs)
CA (1) CA2889466C (cs)
CL (1) CL2015000926A1 (cs)
CR (2) CR20200237A (cs)
EA (1) EA030613B1 (cs)
ES (1) ES2671502T3 (cs)
GE (1) GEP201706690B (cs)
HK (1) HK1213567A1 (cs)
HR (1) HRP20180670T1 (cs)
IL (1) IL238116B (cs)
IN (1) IN2015DN03928A (cs)
MA (1) MA38085B1 (cs)
MX (2) MX372708B (cs)
MY (1) MY186549A (cs)
NZ (1) NZ706723A (cs)
PE (3) PE20151494A1 (cs)
PH (1) PH12015500785A1 (cs)
PL (1) PL2909188T3 (cs)
SA (1) SA515360271B1 (cs)
SG (1) SG11201502795VA (cs)
SI (1) SI2909188T1 (cs)
TR (1) TR201807861T4 (cs)
UA (1) UA115455C2 (cs)
WO (1) WO2014059422A1 (cs)
ZA (1) ZA201502349B (cs)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20151494A1 (es) 2012-10-12 2015-11-06 Exelixis Inc Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
SI3316867T1 (sl) 2015-06-30 2021-08-31 Genentech, Inc. Tablete s takojšnjim sproščanjem, ki vsebujejo zdravilo in postopek za pripravo tablet
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
CN105330643B (zh) * 2015-12-09 2017-12-05 苏州明锐医药科技有限公司 卡比替尼的制备方法
CN106045969B (zh) * 2016-05-27 2019-04-12 湖南欧亚药业有限公司 一种卡比替尼的合成方法
BR112019002036A2 (pt) 2016-08-12 2019-05-14 Genentech Inc métodos de tratamento de um sujeito com câncer colorretal, kit para tratamento do câncer colorretal em um sujeito humano e combinação de fármacos para a terapia do câncer colorretal
WO2018064299A1 (en) 2016-09-29 2018-04-05 Genentech, Inc. Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a taxane
WO2020187674A1 (en) 2019-03-15 2020-09-24 Sandoz Ag Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate
US20240173329A1 (en) 2021-03-09 2024-05-30 Genentech, Inc. Belvarafenib for use in treatment of brain cancers
EP4319749A1 (en) 2021-04-06 2024-02-14 Genentech, Inc. Combination therapy with belvarafenib and cobimetinib or with belvarafenib, cobimetinib, and atezolizumab

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1563587A (en) * 1924-09-20 1925-12-01 Raney Murray Method of preparing catalytic material
US1628190A (en) * 1926-05-14 1927-05-10 Raney Murray Method of producing finely-divided nickel
US1915473A (en) * 1930-12-31 1933-06-27 Raney Murray Method of preparing catalytic material
US4510139A (en) 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
US5155110A (en) 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
WO1995026956A1 (fr) 1994-04-01 1995-10-12 Shionogi & Co., Ltd. Derive d'oxime et bactericide le contenant en tant qu'ingredient actif
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US6251943B1 (en) 1997-02-28 2001-06-26 Warner-Lambert Company Method of treating or preventing septic shock by administering a MEK inhibitor
AU756586C (en) 1997-07-01 2004-01-29 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
NZ501276A (en) 1997-07-01 2000-10-27 Warner Lambert Co 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders
US6974878B2 (en) 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
HUP0104607A3 (en) 1998-12-15 2002-12-28 Warner Lambert Co Use of a mek inhibitor for preventing transplant rejection
HUP0104693A3 (en) 1998-12-16 2003-12-29 Warner Lambert Co Treatment of arthritis with mek inhibitors
JP2002532570A (ja) 1998-12-22 2002-10-02 ワーナー−ランバート・カンパニー 併用化学療法
KR20000047461A (ko) 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
AU2483000A (en) 1999-01-07 2000-07-24 Warner-Lambert Company Treatment of asthma with mek inhibitors
CA2358438A1 (en) 1999-01-07 2000-07-13 David Thomas Dudley Antiviral method using mek inhibitors
JP2002534498A (ja) 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー Mek阻害剤としてのベンゼンスルホンアミド誘導体およびその使用
KR20020002370A (ko) 1999-01-13 2002-01-09 로즈 암스트롱, 크리스틴 에이. 트러트웨인 벤조헤테로사이클 및 mek 억제제로서의 그의 용도
JP2002534515A (ja) 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー 1−複素環置換されたジアリールアミン
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
CA2349180A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett Anthranilic acid derivatives
PL352835A1 (en) 1999-07-16 2003-09-08 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
IL147618A0 (en) 1999-07-16 2002-08-14 Warner Lambert Co Method for treating chronic pain using mek inhibitors
KR20020012315A (ko) 1999-07-16 2002-02-15 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Mek 저해제를 사용한 만성 통증의 치료 방법
EP1202732A2 (en) 1999-07-16 2002-05-08 Warner-Lambert Company Llc Method for treating chronic pain using mek inhibitors
IL155155A0 (en) 1999-09-17 2003-10-31 Cor Therapeutics Inc BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
WO2001068619A1 (en) 2000-03-15 2001-09-20 Warner-Lambert Company 5-amide substituted diarylamines as mex inhibitors
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
AP2001002217A0 (en) 2000-07-19 2001-09-30 Warner Lambert Co 4-IODOPHENYLAMINO BENZHYDROXAMIC ACID OXYGENES ESTERS
MXPA03001654A (es) * 2000-08-25 2004-09-10 Warner Lambert Co Proceso para la elaboracion del acido n-aril-antranilico y sus derivados.
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
NZ518726A (en) 2001-05-09 2004-06-25 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US20040039208A1 (en) * 2001-07-20 2004-02-26 Chen Michael Huai Gu Process for making n-aryl-anthranilic acids and their derivatives
DE10141266A1 (de) 2001-08-21 2003-03-06 Syntec Ges Fuer Chemie Und Tec Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden
US7085492B2 (en) 2001-08-27 2006-08-01 Ibsen Photonics A/S Wavelength division multiplexed device
PL370549A1 (en) 2001-10-31 2005-05-30 Pfizer Products Inc. Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome
BR0307060A (pt) 2002-01-23 2004-10-26 Warner Lambert Co ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
DOP2003000556A (es) 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
EP3000810B1 (en) 2002-03-13 2017-07-19 Array Biopharma, Inc. N3 alkylated benzimidazole derivative as mek inhibitor
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
CN1652792A (zh) 2002-03-13 2005-08-10 阵列生物制药公司 作为mek抑制剂的n3烷基化苯并咪唑衍生物
CA2488567A1 (en) 2002-06-11 2003-12-18 Merck & Co., Inc. (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
WO2004004644A2 (en) 2002-07-05 2004-01-15 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
MXPA05009459A (es) 2003-03-03 2006-05-17 Array Biopharma Inc Inhibidores de p38 y sus metodos de uso.
JP2005162727A (ja) 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
TW200505834A (en) 2003-03-18 2005-02-16 Sankyo Co Sulfamide derivative and the pharmaceutical composition thereof
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
JP2007516161A (ja) 2003-06-20 2007-06-21 セルテック アール アンド ディ リミテッド キナーゼ阻害剤としてのチエノピリドン誘導体
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
US20050049276A1 (en) 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
ES2331246T3 (es) 2003-07-24 2009-12-28 Warner-Lambert Company Llc Derivados de benzamidazol como inhibidores del mek.
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
TW200520745A (en) 2003-09-19 2005-07-01 Chugai Pharmaceutical Co Ltd Novel 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
DK1689233T3 (da) 2003-11-19 2012-10-15 Array Biopharma Inc Bicykliske inhibitorer af MEK
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
EP1694673B1 (en) 2003-12-08 2008-01-16 F.Hoffmann-La Roche Ag Thiazole derivates
TWI361066B (en) 2004-07-26 2012-04-01 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
CN101065358B (zh) * 2004-10-20 2015-03-11 默克雪兰诺有限公司 3-芳基氨基吡啶衍生物
WO2006061712A2 (en) 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
BRPI0617165B1 (pt) 2005-10-07 2023-10-03 Exelixis Inc Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
AU2007284562B2 (en) 2006-08-16 2013-05-02 Exelixis, Inc. Using PI3K and MEK modulators in treatments of cancer
CN101605540A (zh) 2006-12-14 2009-12-16 埃克塞利希斯股份有限公司 使用mek抑制剂的方法
PE20151494A1 (es) 2012-10-12 2015-11-06 Exelixis Inc Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer
EP3103789B1 (en) 2014-02-07 2018-10-31 Sumitomo Chemical Company Limited Method for producing (r)-1,1,3-trimethyl-4-aminoindane
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Also Published As

Publication number Publication date
AU2013328929B2 (en) 2018-01-04
MX2020005533A (es) 2020-10-12
SI2909188T1 (en) 2018-07-31
IL238116B (en) 2018-06-28
EP2909188A1 (en) 2015-08-26
US20200392104A1 (en) 2020-12-17
HRP20180670T1 (hr) 2018-07-13
CN104837826A (zh) 2015-08-12
CN104837826B (zh) 2018-07-27
EA201590700A1 (ru) 2015-09-30
CR20150245A (es) 2015-11-19
MY186549A (en) 2021-07-26
PH12015500785B1 (en) 2015-06-15
CR20200237A (es) 2020-07-26
US10239858B2 (en) 2019-03-26
MA38085B1 (fr) 2018-11-30
HK1213567A1 (zh) 2016-07-08
JP2018052973A (ja) 2018-04-05
TR201807861T4 (tr) 2018-06-21
PE20191818A1 (es) 2019-12-27
CA2889466A1 (en) 2014-04-17
CN108948043A (zh) 2018-12-07
CN108948043B (zh) 2021-05-04
CL2015000926A1 (es) 2015-08-28
PE20200387A1 (es) 2020-02-24
PE20151494A1 (es) 2015-11-06
US20170349569A1 (en) 2017-12-07
PL2909188T3 (pl) 2018-08-31
ZA201502349B (en) 2019-12-18
US20190185447A1 (en) 2019-06-20
US9771347B2 (en) 2017-09-26
ES2671502T3 (es) 2018-06-06
MX372708B (es) 2020-05-29
EA030613B1 (ru) 2018-08-31
KR102204520B1 (ko) 2021-01-20
SA515360271B1 (ar) 2016-05-19
SG11201502795VA (en) 2015-05-28
US20150210668A1 (en) 2015-07-30
GEP201706690B (en) 2017-06-26
PH12015500785A1 (en) 2015-06-15
BR112015008113A2 (pt) 2017-07-04
KR20150067339A (ko) 2015-06-17
US10793541B2 (en) 2020-10-06
CA2889466C (en) 2021-09-14
AU2013328929A1 (en) 2015-04-30
NZ706723A (en) 2018-07-27
US11414396B2 (en) 2022-08-16
BR112015008113B1 (pt) 2022-05-24
MX2015004660A (es) 2015-08-07
EP2909188B1 (en) 2018-03-07
MA38085A1 (fr) 2018-08-31
JP2015533175A (ja) 2015-11-19
JP6300042B2 (ja) 2018-03-28
HK1213878A1 (en) 2016-07-15
UA115455C2 (uk) 2017-11-10
WO2014059422A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
IN2015DN03928A (cs)
PH12015502284A1 (en) Protein kinase inhibitors
NZ705705A (en) Ret inhibitor
PH12016500225A1 (en) Novel quinoline-substituted compound
MA40076A (fr) Inhibiteurs de syk
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
IN2015DN02929A (cs)
UA116239C2 (uk) Нові похідні піридину
TN2013000400A1 (en) Imidazopyridazines as akt kinase inhibitors
PH12015500363A1 (en) Prodrugs of amino quinazoline kinase inhibitor
NZ736970A (en) Process methods for phosphatidylinositol 3-kinase inhibitors
PH12017500747A1 (en) Heterocyclic compound
MX351863B (es) Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo.
PH12015502032A1 (en) Azetidinyloxyphenylpyrrolidine compounds
UA111333C2 (uk) Спосіб одержання l-аргінінової солі периндроприлу
IN2014DN10658A (cs)
MX2015012523A (es) Metodos para elaborar composiciones antineoplasicas.
IN2014KN01772A (cs)
GEP20176633B (en) Use of pidotimod to treat psoriasis
MY177247A (en) Method of production of human insulin methyl ester
IN2013MU02595A (cs)
GEP201706683B (en) Usage of pidotimod to treat inflammatory bowel diseases
UA58841U (ru) Способ профилактики и оздоровления поросят